Because glimepiride can induce insulin secretion to reduce blood glucose levels as well as CLIP3 activation, a decrease in blood glucose levels upon treatment of glimepiride might explain the significant in vivo efficacy in GBM mouse models. The gene discussed is CLIP3; the disease is glioblastoma.